Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients research hub

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer (BR31)

This study is looking at a new drug called durvalumab (also known as MEDI4736) for people who have had surgery for a certain type of lung cancer. It aims to see if the drug can stop the cancer from coming back, especially in those with specific cancer markers.